

Epidemiology, Risk Factors and Outcomes of Bloodstream Infection Caused by ESKAPEEC Pathogens Among Hospitalized Children

Xiaoshan Peng

Sichuan University West China Second University Hospital

Wei Zhou

Sichuan University West China Second University Hospital

Yu Zhu

Sichuan University West China Second University Hospital

Chaomin Wan (✉ wcm0220@126.com)

West China Second University Hospital <https://orcid.org/0000-0003-1480-3050>

Research article

Keywords: ESKAPEEC pathogens, bloodstream infection, children

Posted Date: August 3rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-51676/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pediatrics on April 21st, 2021. See the published version at <https://doi.org/10.1186/s12887-021-02661-9>.

Abstract

Background: Bloodstream infection (BSI) resulting from the ESKAPEE_c pathogens is relevant to high mortality and economic cost. Data concerning the impact of BSI due to ESKAPEE_c in pediatric population was virtually scant. Our purpose was to summarize the epidemiology, risk factors and outcomes of ESKAPEE_c BSI among hospitalized children.

Methods: Inpatients diagnosed with BSI with definite etiology between January 2016 and December 2018 were enrolled retrospectively at the West China Second University Hospital. Data were systematically reviewed on patient' clinical characteristics and laboratory findings to ascertain independent predictors, clinical features and outcomes.

Results: Of the 228 patients with BSI, 174 (76.0%) were caused by ESKAPEE_c (124 MDR-ESKAPEE_c). Multivariate analysis demonstrated that premature and/ or low birth weight (odds ratio [OR] = 2.981, P=0.036), previous surgery and/or trauma (OR=5.71, P=0.029) and source of urinary tract infection (OR=10.6, P=0.004) were independently associated with ESKAPEE_c BSI. The independent risk factor for MRD-ESKAPEE_c BSI was nosocomial infection (OR=3.314, P=0.037). The overall mortality rate in patients with ESKAPEE_c BSI was 14.0% (25/174), and no significant difference was ascertained in mortality between MRD-ESKAPEE_c and non-MRD ESKAPEE_c BSI groups (13.7% vs. 11.4%, P=0.692). In addition, previous surgery and/or trauma, thrombocytopenia, mechanical ventilation were significant risk factors for mortality caused by ESKAPEE_c BSI.

Conclusions: More than two-thirds of BSI among hospitalized children were caused by ESKAPEE_c. Previous surgery and/or trauma, thrombocytopenia and mechanical ventilation increased the risk rate for mortality in ESKAPEE_c BSI. The risk factors ascertained could assist physicians to early suspect ESKAPEE_c and MDR ESKAPEE_c.

Background

The notorious group of pathogens, *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Escherichia coli*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* spp, named "ESKAPEE_c" owing to their high resistances to multiple antimicrobial agents, have recently aroused global concern [1–2]. Currently, the incidence of bloodstream infection (BSI) caused by ESKAPEE_c has increased rapidly [3], and ESKAPEE_c BSI brought about worse outcomes [3], longer hospital stays, higher economic costs [4–6], and increased mortality [4–6]. In addition, effective antimicrobial agents against ESKAPEE_c strains were limited due to the growth of resistance to multiple antibiotics in these bacterial species. Inappropriate and delayed empirical antimicrobial agents treatment for patients with BSI was connected with high risk of mortality [7–10]. Therefore, a wide understanding of the main clinical characteristics of ESKAPEE_c BSI among hospitalized children was crucial for physicians to early recognition and select proper empirical therapy .

To our knowledge, the existing studies have given attention to the epidemiology and antimicrobial resistance trends of ESKAPEE_c in patients with BSI [11–13], and clinical data about ESKAPEE_c BSI were only available in adult populations with cancer or solid organ transplantation [14–17]. Currently, there was no data concerning the BSI caused by ESKAPEE_c in pediatric populations. Thus, we sought to investigate the epidemiology, clinical characteristics among hospitalized children with ESKAPEE_c BSI. Simultaneously, we also assessed risk factors, and clinical outcomes.

Methods

Study population

Hospitalized children who were diagnosed with BSI based on a positive blood culture between 2016 and 2018 at the West China Second University Hospital of Sichuan University and aged under 14 years old were enrolled retrospectively after obtaining ethics approval. The exclusion criteria were listed next (Fig 1): (1) polymicrobial infections ;(2) diagnosed with fungal BSI; (3) incomplete clinical data.

Data Collection

This study obtained the following data from electronic medical records—including age, sex, previous hospitalization (within 1 month), previous surgery and/ or trauma (within 3 months), previous antibiotic use (within 1 month), underlying diseases, nosocomial infection or not, symptoms, microbiology data (microorganisms and resistance to antimicrobial agents), likely source of infection, blood products transfusion, pediatric intensive care unit (PICU) admission, invasive operation (indwelling gastric tube, central venous catheter, urinary catheter, mechanical ventilation), empirical antibiotics therapy, length of hospital stay and patients' clinical outcomes. Meanwhile, the other laboratory results were collected within one day of admission: the blood routine, C-reactive protein, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This study was analyzed through three parts. First, all enrolled patients were classified into ESKAPEE_c and non-ESKAPEE_c groups to ascertain the risk factors of ESKAPEE_c BSI. Second, risk factors of patients with BSI resulting from MRD ESKAPEE_c were investigated by comparing the MRD ESKAPEE_c and non-MRD ESKAPEE_c groups. Finally, the 174 patients with ESKAPEE_c BSI according to patients' final condition at discharge were divided into survivor and non-survivor groups to investigate the risk factors closely connected with mortality.

Definitions

Bloodstream infection was defined as the causative bacteria isolated in the blood cultures and clinical manifestations in accordance with sepsis syndrome [18]. The diagnosis criteria were determined by the definitions of National Healthcare Safety Network and CDCP [19]. ESKAPEE_c were previously defined elsewhere [1-2,4,12]. The definition of MRD was based on the international expert proposal for interim standard [20]. Polymicrobial infection referred to ≥ 2 causative organisms isolated from a single blood culture [21]. Empirical antibiotic treatment was regarded as being “appropriate” if the isolated causative organisms were susceptible to ≥ 1 of the antimicrobial agents administered in vitro. Otherwise, the

treatment was considered to be “inappropriate”. Overall mortality referred to death by any cause during hospitalization. Some children were discharged automatically from PICU or other departments ignoring the physician’s proposal When further cure was presumed to be futile. These children in the presence of multiple organ failure, demanding inotropes support or mechanical ventilation were considered dead within this period.

Microbiological Methods

The blood cultures were fulfilled strictly in accordance with the standard operating procedures. The causative bacteria identification and antibiotic resistance testing were conducted using the VITEK 2 (BioMérieux, Marcy-l'Étoile, France) system. The interpretation criteria of antibiotic resistance tests was determined by the definitions of Clinical and Laboratory Standards Institute (2017) [22].

Statistical Analysis

We reported the median (interquartile range [IQR]) for measurement dates and analyzed them using Mann-Whitney U test appropriately. We calculated constituent ratios for count dates and analyzed them utilizing the χ^2 test or Fisher’s exact test. Variables in the univariate analysis that exhibited statistical differences (P-value < 0.05) were placed into the binary logistic regression analysis to investigate factors potentially associated with ESKAPEE_c/MRD-ESKAPEE_c BSI and mortality. All dates were implemented with the SPSS version 22.0. P-values <0.05 were deemed significant.

Results

252 hospitalized pediatric patients were diagnosed with laboratory-confirmed BSI Between 2016 and 2018 at the West China Second Hospital, Sichuan University. Twenty-four patients were not included according to the exclusion criteria (Fig 1); Ultimately, we identified 228 patients in this study. 174 of the 228 patients(76.0%) had ESKAPEE_c BSI. 6 of the 174 (3%) patients lacked resistance data; 124 (74%) were MDR ESKAPEE_c and 44 (26%) were non-MDR ESKAPEE_c.

Microbiology

As Table 1 showed, the two leading ESKAPEE_c pathogens were *Escherichia coli* (26.8%,61/228), *Klebsiella pneumoniae* (20.2%,46/228), followed by *Enterococcus faecium* (12.7%, 29/228), *Staphylococcus aureus* (12.7%, 29/228), *Acinetobacter baumannii* (2.6%, 6/228), *Pseudomonas aeruginosa* (1.3%, 3/228) and *Enterobacter* spp (0). Of the 124 MDR ESKAPEE_c strains, *Escherichia coli* and *Klebsiella pneumoniae* accounted for nearly 65.3%. 42 (33.9%) were ESBL-producing bacteria, including *Escherichia coli* (28,22.6%) and *Klebsiella pneumoniae* (14,11.3%). 20 (16.1%) were carbapenem non-susceptibility bacteria, including *Klebsiella pneumoniae* (15,12.1%), *Escherichia coli* (3,2.4%) and *Acinetobacter baumannii* (2,1.6%). In addition, there were 1 vancomycin-resistant *Enterococcus faecium* and 8 methicillin-resistant *Staphylococcus aureus*.

Comparison of ESKAPEEec and non-ESKAPEEec BSI

The main characteristics of patients with ESKAPEEec and non-ESKAPEEec BSI were summarized in Table 2. Less than half of the patients were males (42.1%, 96/228) and the median age was 4.4 (range:0.7-35.7) months. The median age between the two groups (median month, 2.5 [0.5-12.3] vs 32.7[8.0-100.4], $P<0.001$) showed statistically significant difference. Regarding underlying disease, a greater proportion of premature and/or low birth weight (31.6% vs 9.3%, $P=0.001$), tumor diseases (16.7% vs 0%, $P < 0.001$) was presented in patients with ESKAPEEec BSI. Compared with non-ESKAPEEec BSI, patients with BSI caused by ESKAPEEec had increased percentages of previous surgery and/ or trauma(13.8% vs 3.7%, $P=0.042$), nosocomial infection (32.2% vs 7.5%, $P<0.001$), more source of urinary tract infection (14.9% vs 1.9%, $P=0.009$), but lower rate of previous antibiotic use (25.9% vs 50.0%, $P=0.001$), less source of lung infection(17.8% vs 42.6%, $P<0.001$), intracranial infection(1.1% vs 16.7%, $P<0.001$) and lower levels of platelet count (median, 209 [111-323] vs 341 [168-439], $P<0.001$) , C-reactive protein (median mg/dL,15.0 [3.0-85.3] vs 26.5 [10.0-116.6], $p=0.017$). After applying the multivariate analysis, premature and/or low birth weight (odds ratio [OR]=2.981, $P=0.036$), previous surgery and/or trauma (OR=5.71, $P=0.029$) and source of urinary tract infection (OR=10.6, $P=0.004$) were independent risk factors for ESKAPEEec BSI. Source of intracranial infection was a protective factor for ESKAPEEec BSI(OR=0.198, $P=0.037$).

In terms of empiric antimicrobial treatment and outcomes of all cases, we found that 50 of the 228 patients (21.9%) were treated inappropriately:46 (27.4%, 46/174) were in ESKAPEEec BSI patient group and 4 (7.5%,4/54) were in non-ESKAPEEec BSI group. Patients with ESKAPEEec BSI had received inappropriate empiric antibiotics treatment significantly more often (27.4% vs 7.5%, $p=0.003$)(Table 2). Although no significant differences in the MODS, septic shock, mechanical ventilation, PICU admission and mortality between ESKAPEEec and non-ESKAPEEec BSI groups were found (all $p>0.05$). Patients with BSI due to ESKAPEEec had longer hospital stay (median days, 20.5[10.0–31.0] vs 14.0[8.8–23.0], $p=0.023$) compared with those with non-ESKAPEEec BSI.

Comparison of MDR ESKAPEEec and non-MDR ESKAPEEec BSI

The 168 patients with resistance data were divided into MDR ESKAPEEec and non-MDR ESKAPEEec BSI groups. The differences of the main characteristics between the 2 groups were showed in Table 3. MDR ESKAPEEec patients with BSI had more nosocomial infections (41.1% vs 11.4%, $P<0.001$) and the presence of underlying disease (72.6% vs 43.2%, $P < 0.001$) was also higher, whereas the age and sex between the 2 groups were not statistically different. Compared with non-MDR ESKAPEEec BSI, patients with MDR-ESKAPEEec BSI were less likely to have a history of antibiotic use within 1 month (21.8% vs 43.2%, $P= 0.006$), source of skin or soft tissue infection (6.5% vs 27.3%, $P<0.001$). Furthermore, the median level of platelet count was significantly lower in MDR-ESKAPEEec group with BSI than that in non-MDR ESKAPEEec group (median,188[100-302] vs 271[173-413], $P=0.004$). In multivariate analysis, the independent risk factor for MRD-ESKAPEEec BSI was nosocomial infection (OR=3.314, $P=0.037$), while the skin or soft tissue infection (OR=0.245, $P=0.011$) was a protective predictor of MRD ESKAPEEec BSI.

Regarding empiric antimicrobial treatment and outcomes for MRD ESKAPEE_c BSI, 42 of the 124 MDR-ESKAPEE_c patients with BSI (33.9%) were treated inappropriately in comparison with the 4 of the 44 non-MDR ESKAPEE_c patients with BSI (9.1%) (P=0.002) (Table 3). Hospital stay in MDR-ESKAPEE_c BSI group was longer than that in non-MDR ESKAPEE_c BSI group (median days, 24.0 [13.0-36.0] vs 14.5 [9.0-27.3], P=0.006) (Table 3). Whereas, no significant differences were ascertained in MODS, septic shock, mechanical ventilation, PICU admission, mortality between MDR and non-MDR ESKAPEE_c BSI groups (all p>0.05).

Predictors for mortality among hospitalized children with ESKAPEE_c BSI.

A total of 174 hospitalized children with ESKAPEE_c BSI were identified in our study. The overall mortality rate of these patients was 14.0% (25/174), and no significant difference was ascertained regarding mortality between MRD-ESKAPEE_c and non-MRD ESKAPEE_c BSI groups (13.7% vs. 11.4%, P=0.692) (Table 3). In the univariate analysis (Table 4), previous surgery and/or trauma, previous antibiotic use, neutrophil percentage, hemoglobin, platelet count, MODS, blood products transfusion, mechanical ventilation, PICU admission were statistically differences between survivor and non-survivor groups (all p<0.05). A multivariate analysis demonstrated that previous surgery and/or trauma (OR=7.006, P=0.006), mechanical ventilation (OR=7.997, P= 0.004) appeared to be effective predictors for death. Previous antibiotic use (OR=0.132, P=0.034), normal platelet count (OR=0.996, P= 0.037) were protective factors for death caused by ESKAPEE_c BSI.

Discussion

Data concerning the burden of ESKAPEE_c BSI in hospitalized children was indeedly non-existent. Existing information was mainly in adult population with definite underlying diseases. There were several findings identified in this study: (1) 76% (n = 174) of BSIs among hospitalized children were caused by ESKAPEE_c (124 MDR-ESKAPEE_c). (2) Several risk factors for BSI due to ESKAPEE_c and associated with BSI caused by MRD ESKAPEE_c were identified. (3) The overall mortality rate in patients with ESKAPEE_c BSI was 14.0% (25/174), and no significant difference was ascertained in mortality rate between MRD-ESKAPEE_c and non-MRD ESKAPEE_c BSI groups (13.7% vs. 11.4%, P = 0.692). (4) Several predictors for mortality among hospitalized children with ESKAPEE_c BSI were also summarized.

In the current study, 76% of BSIs were caused by ESKAPEE_c, which was similar to the previous reports in southwest China (58.7%) [12], Rome (61.7%) [13], but higher than that in US (27.2%) [11]. This discrepancy may be associated with geographical regions and study population. Previous frequently reported MDR bacteria were *Escherichia coli* and *Klebsiella pneumoniae*, most of which trend to be ESBL-producing organisms [23–25]. Furthermore, an upward trend in the proportion of ESBL-producing Enterobacteriaceae ESKAPEE_c BSI was found [12]. Similarly, a high rate of MRD-ESKAPEE_c BSI resulting from an ESBL-producing strain among children was also observed in this study. One common reason in many developing countries which may result in the high incidence of antibiotic resistant BSI was the overuse and misuse of antibiotics. Meanwhile, our study revealed that the most common carbapenem non-

susceptibility strains were *Klebsiella pneumoniae* (6.8%,15/222), which was in agreement with data reported by CHINET(5.5%) [26], but differed from the literature from southwest China(12.8%) [12]. Studies have shown that carbapenem-resistant *Klebsiella pneumoniae* (CRKP) was relevant to high mortality[27–28]. Yet the treatment regimens for CRKP BSI were limited in clinic. CRKP infections have posed an extreme antibiotic-resistant threat [28]. Thus, further studies in the mechanism of CR K. pneumoniae production and infection control are urgently needed.

To our knowledge, there was no study using multivariate analyses to investigate risk factors for ESKAPEE_c BSI. In the present study, we found that premature and/ or low birth weight, previous surgery and/or trauma and source of urinary tract infection were independent risk factors for ESKAPEE_c BSI. Moreover, there was only two studies among adult population focusing on the risk factors for drug-resistant ESKAPEE_c BSI in multivariate analyses [14–15]. Gudiol C, et al. in 2014 have found that drug-resistant ESKAPEE_c bacteremia were significantly associated with underlying diseases, previous antibiotic use, and source of urinary tract infection [14]. Marta B, et al. in 2013 have revealed that solid-organ transplant patients who had high percentages of previous transplantation, previous antibiotic use, and septic shock were more likely to develop drug-resistant ESKAPEE_c bacteremia [15]. Based on the existing information, it was likely that underlying diseases, previous invasive operation, previous antibiotic use and source of infection were the keys factors for MRD-ESKAPEE_c BSI. However, several of these risk factors were not ascertained according to our study, and we further investigated the independent risk factor for MRD ESKAPEE_c patients with BSI was nosocomial infection (OR = 3.314, P = 0.037). The discrepancies may be owing to the diverse study population, diverse definition of MRD [14–17], diverse inclusion criteria [14–17]. Various studies have showed that ESKAPEE_c pathogens, especially MRD-ESKAPEE_c, have emerged as the predominant opportunistic organisms responsible for nosocomial infections [29–31], resulting in severe infection. Accompanying by nosocomial infection, there was urgently need for empiric treatment to cover MRD-ESKAPEE_c pathogens among children with BSI. The association between bacterial resistance development and previous antibiotic use remained inconsistent. Some studies revealed that previous antibiotic exposure(especially carbapenem) was an independent risk factor for MRD pathogens infection [14–15, 28, 32]. Conversely, other study has demonstrated no association was identified between MRD bacterial infections and previous antibiotic use [33], in accordance with our data. Thus, further association between bacterial resistance development and antibiotic use previous to infection need to be monitored closely.

To explore the possible influence of MRD pathogens for the outcome of patients with ESKAPEE_c BSI, patients' characteristics were systematically evaluated. The overall mortality rate among children with ESKAPEE_c BSI was 14.0% (25/174), and no significant difference was ascertained in mortality between MRD-ESKAPEE_c and non-MRD ESKAPEE_c BSI patients (13.7% vs. 11.4%, P = 0.692), which was in accordance with previous studies [16–17]. This finding reflected the fact that MRD-ESKAPEE_c was not a risk factor associated with worse outcome, and although resistant strains were not easily to cure, might be less virulent. Moreover, previous studies have reported various predictors of poor outcome in patients with ESKAPEE_c BSI, including female sex [16], lymphocyte counts < 300/mm³(16), corticosteroid therapy

[14] and β -lactam monotherapy [14], septic shock [16–17], ICU admission [14]. In our study, we found that mechanical ventilation (OR = 7.997, P = 0.004) was the strongest risk factor associated with mortality. Further, previous surgery and/or trauma and thrombocytopenia increased the risk rates for mortality among children with ESKAPEE_c BSI. Thrombocytopenia was a well-known indicator of serious infections development [34–35], which can be considered an early screening tool for poor outcome in children with ESKAPEE_c BSI. Low platelet count resulting from bacterial infection was recorded closely and trended to indicate impaired production caused by bone marrow suppression and/or increased destruction owing to endothelial cell injury and platelet aggregation [36–38].

Though it is the first time to summarize the main characteristics of ESKAPEE_c BSI among hospitalized children, several limitations exist. First, our study is a single-center study representing most of the pediatric population in the Southwest China, some findings may not be generalizable to other settings. Second, selection and recall bias occurred inevitably due to the retrospective analysis and these variations may partly affect the findings of the study.

Abbreviations

ALT, alanine aminotransferase ; AST, aspartate aminotransferase ; BSI, bloodstream infection ; CI, confidence interval ; MODS, multiple organ dysfunction syndrome ; MDR, multidrug resistant ; IQR, interquartile range ; OR, odds ratio ; PICU, pediatric intensive care unit

Declarations

1. Ethics approval and consent to participate

Ethical approval for this study was approved by the medical committee of West China Second Hospital, Sichuan University. Owing to the retrospective design of this research, informed consent was waived.

2. Consent for publication

Not applicable.

3. Availability of data and material

Not applicable.

4. Competing interests

The authors declare that they have no competing interests.

5. Funding

Supported by the grant from Pediatric Clinical Research Center Foundation of Sichuan Province, China (No.2017-46-4).

6. Authors' contributions

SPYZ and CW designed this research. WZ and SP collected the data. SP interpreted the data, and drafted the initial manuscript. All authors read and approved the final manuscript.

7. Acknowledgements

Not applicable.

References

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Jan 1;48(1):1-12.
2. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018 Mar;18(3):318-327.
3. Pogue JM, Kaye KS, Cohen DA, et al. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. *Clin Microbiol Infect*. 2015 Apr;21(4):302-12.
4. Marturano JE, Lowery TJ. ESKAPE Pathogens in Bloodstream Infections Are Associated With Higher Cost and Mortality but Can Be Predicted Using Diagnoses Upon Admission. *Open Forum Infect Dis*. 2019 Nov 22;6(12):ofz503.
5. Zhen X, Lundborg CS, Sun X, et al. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. *Antimicrob Resist Infect Control*. 2019 Aug 13;8:137.
6. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PLoS One*. 2017 Dec 21;12(12):e0189621.
7. Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance. *Clin Infect Dis*. 2020 Mar 3;70(6):1068-1074.
8. Tacconelli E, Cataldo MA, Mutters NT, et al. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β -lactamase-producing Enterobacteriaceae infections. *Int J Antimicrob Agents*. 2019 Jul;54(1):49-54.
9. Retamar P, Portillo MM, López-Prieto MD, et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. *Antimicrob Agents Chemother*. 2012 Jan;56(1):472-8.
10. Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. *N Engl J Med* 2017;376:2235-44.

11. Larru B, Gong W, Vendetti N, et al. Bloodstream infections in hospitalized children: epidemiology and antimicrobial susceptibilities. *Pediatr Infect Dis J*. 2016;35(5):507–10.
12. Yang S, Xu H, Sun J, Sun S. Shifting trends and age distribution of ESKAPE^{Ec} resistance in bloodstream infection, Southwest China, 2012-2017. *Antimicrob Resist Infect Control*. 2019 Mar 29;8:61.
13. Angelis G De, Fiori B, Menchinelli G, et al. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and *Escherichia coli* at a large teaching hospital in Rome, a 9-year analysis (2007–2015). *Eur J Clin Microbiol Infect Dis* 2018; 37(9):1627–1636.
14. Bodro M, Gudiol C, Garcia-Vidal C, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. *Support Care Cancer*. 2014 Mar;22(3):603-10.
15. Bodro M, Sabé N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. *Transplantation*. 2013 Nov 15;96(9):843-9.
16. Song SH, Li XX, Wan QQ, et al. Risk factors for mortality in liver transplant recipients with ESKAPE infection. *Transplant Proc*. 2014 Dec;46(10):3560-3.
17. Ye QF, Zhao J, Wan QQ, et al. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality. *Transpl Infect Dis*. 2014 Oct;16(5):767-74.
18. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 2013;39:165–228.
19. Centers for Disease Control and Prevention. CDC/ NHSN Surveillance Definitions for Specific Types of Infections. Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf. Accessed 15 January 2014.
20. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012 Mar;18(3):268-81.
21. Zheng C, Zhang S, Chen Q, et al. Clinical characteristics and risk factors of polymicrobial *Staphylococcus aureus* bloodstream infections. *Antimicrob Resist Infect Control*. 2020 May 27;9(1):76.
22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI document M100. Wayne, PA; CLSI; 2017.
23. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. *Biomed Res Int*. 2016;2016:2475067.
24. Seni J, Mwakyoma AA, Mashuda F, et al. Deciphering risk factors for blood stream infections, bacteria species and antimicrobial resistance profiles among children under five years of age in North-Western Tanzania: a multicentre study in a cascade of referral health care system. *BMC Pediatr*. 2019 Jan 26;19(1):32.

25. Xiao T, Yang K, Zhou Y, et al. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing *Escherichia coli* bacteremia: a retrospective study from 2013 to 2016. *Antimicrob Resist Infect Control*. 2019 Aug 27;8:144.
26. Xu A, Zheng B, Xu Y, et al. National epidemiology of carbapenem-resistant and extensively drug-resistant gram-negative bacteria isolated from blood samples in China in 2013. *Clin Microbiol Infect*. 2016; 22(S1):S1–8.
27. Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection in a tertiary hospital in North China. *Antimicrob Resist Infect Control*. 2020 Jun 1;9(1):79.
28. Xiao T, Zhu Y, Zhang S, et al. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant *Klebsiella pneumoniae* Bacteremia in Nontransplant Patients. *J Infect Dis*. 2020 Mar 16;221(Supplement_2):S174-S183.
29. Dramowski A, Madide A, Bekker A. Neonatal nosocomial bloodstream infections at a referral hospital in a middle-income country: burden, pathogens, antimicrobial resistance and mortality. *Paediatr Int Child Health*. 2015Aug;35(3):265-72.
30. Tian L, Sun Z, Zhang Z. Antimicrobial resistance of pathogens causing nosocomial bloodstream infection in Hubei Province, China, from 2014 to 2016: a multicenter retrospective study. *BMC Public Health*. 2018 Sep 15;18(1):1121.
31. Choi JY, Kwak YG, Yoo H, et al. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS). *J Hosp Infect*. 2016 Apr;92(4):363-71.
32. Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. *Pediatrics*. 2014 Feb;133(2):e322-9.
33. Aizawa Y, Shoji T, Ito K, et al. Multidrug-resistant Gram-negative Bacterial Bloodstream Infections in Children's Hospitals in Japan, 2010-2017. *Pediatr Infect Dis J*. 2019 Jul;38(7):653-659.
34. Furuichi M, Miyairi I. Risk factors for persistent bacteremia in infants with catheter-related bloodstream infection due to coagulase-negative *Staphylococcus* in the neonatal intensive care unit. *J Infect Chemother*. 2016 Dec;22(12):785-789.
35. Fica A, Bunster N, Aliaga F, et al. Bacteremic pneumococcal pneumonia: serotype distribution, antimicrobial susceptibility, severity scores, risk factors, and mortality in a single center in Chile. *Braz J Infect Dis*. 2014 Mar-Apr;18(2):115-23.
36. Del Vecchio A. Evaluation and management of thrombocytopenic neonates in the intensive care unit. *Early Hum Dev*. 2014 Sep;90 Suppl 2:S51-5.
37. De Stoppelaar SF, Van 't Veer C, Van der Poll T. The role of platelets in sepsis. *Thromb Haemost*. 2014 Oct;112(4):666-77.

Tables

Table 1

Bacteria isolated in hospitalized children with bloodstream infection

Organism	N (%)	MDR ESKAPEEC, N(%)
<i>Enterococcus faecium</i>	29 (12.7)	23 (18.5)
<i>Staphylococcus aureus</i>	29 (12.7)	12 (9.7)
<i>Klebsiella pneumoniae</i>	46 (20.2)	34 (27.4)
<i>Pseudomonas aeruginosa</i>	3 (1.3)	3 (2.4)
<i>Acinetobacter baumannii</i>	6 (2.6)	5 (4.0)
Enterobacter spp	0	0
<i>Escherichia coli</i>	61 (26.8)	47 (37.9)
<i>Streptococcus pneumoniae</i>	27 (11.8)	
Group B <i>Streptococcus</i>	9 (3.9)	
<i>Enterococcus faecalis</i>	5 (2.2)	
Salmonella spp	13 (5.7)	
Total	228(100)	124(100)
Abbreviations: MDR, multidrug resistance.		

Table 2

Comparison of ESKAPEEC and non-ESKAPEEC bloodstream infections among hospitalized children.

Variable	ESKAPEEC n = 174	Non- ESKAPEEC n = 54	Univariate analysis	Logistic Regression Analysis [#]	
			P Value	P Value	Odds Ratio (95% CI)
Male, No. (%)	71(40.8)	25(46.3)	0.475		
Age (m),Median(IQR)	2.5(0.5– 12.3)	32.7(8- 100.4)	< 0.001	0.367	1.004(0.995– 1.014)
Presence of any underlying disease, No. (%)	111(63.8)	14(25.9)	< 0.001		
Premature and/or low birth weight,No. (%)	55(31.6)	5(9.3)	0.001	0.036	2.981(1.076– 8.257)
Tumor diseases, No. (%)	29(16.7)	0	< 0.001	0.262	2.476(0.508– 12.077)
Aplastic anemia, No. (%)	3(1.7)	2(3.7)	0.737		
Congenital heart disease, No. (%)	11(6.3)	1(1.9)	0.349		
Lung disease, No. (%)	12(6.9)	1(1.9)	0.289		
Digestive disease,No. (%)	15(8.6)	1(1.9)	0.163		
Kidney disease,No. (%)	4(2.3)	1(1.9)	1.000		
Other diseases,No. (%)	11(6.3)	3(5.6)	1.000		
Nosocomial infection, No. (%)	56 (32.2)	4 (7.5)	< 0.001	0.579	1.39(0.435– 4.447)
Previous surgery and/ or trauma (within 3 months), No. (%)	24(13.8)	2(3.7)	0.042	0.029	5.71(1.191– 27.384)
Previous hospitalization (within 1 month),No. (%)	33(19.0)	7(13.0)	0.311		
Previous antibiotic use (within 1 month), No. (%)	45(25.9)	27(50.0)	0.001		

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSI, bloodstream infection; MODS, multiple organ dysfunction syndrome; IQR, interquartile range; CI, confidence interval; PICU, pediatric intensive care unit.

Boldface type means $P < .05$. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45 U/L.

[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.181.

Variable	ESKAPEEC n = 174	Non- ESKAPEEC n = 54	Univariate analysis	Logistic Regression Analysis [#]	
			P Value	P Value	Odds Ratio (95% CI)
Penicillins, No. (%)	8(4.6)	7(13.0)	0.064		
Cephalosporins, No. (%)	21(12.1)	18(33.3)	< 0.001	0.168	0.558(0.243– 1.279)
β-lactam-β-lactamase inhibitor combination regimens, No. (%)	18(10.3)	3(5.6)	0.427		
Carbapenems, No. (%)	6(3.4)	2(3.7)	1.000		
Macrolides, No. (%)	1(0.6)	3(5.6)	0.065		
Glycopeptides, No. (%)	8(4.6)	0	0.238		
Others, No. (%)	1(0.6)	3(5.6)	0.065		
Likely source of infections					
Lung infection, No. (%)	31(17.8)	23(42.6)	< 0.001	0.098	0.533(0.254– 1.122)
Abdominal infection, No. (%)	27(15.5)	5(9.3)	0.247		
Urinary infection, No. (%)	26(14.9)	1(1.9)	0.009	0.004	10.6(2.118– 53.044)
Intracranial infection, No. (%)	2(1.1)	9(16.7)	< 0.001	0.037	0.198(0.043– 0.906)
Skin or soft tissue infection, No. (%)	20(11.5)	1(1.9)	0.061		
Primary BSI, No. (%)	75(43.1)	16(29.6)	0.077		
Laboratory findings					
White blood cell count (*10 ⁹), Median(IQR)	9.4(5.0– 13.7)	11.1(6.4– 17.0)	0.106		
Neutrophil percentage, Median(IQR)	56.0(33.9– 71.8)	56.9(37.4– 76.5)	0.370		

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSI, bloodstream infection; MODS, multiple organ dysfunction syndrome; IQR, interquartile range; CI, confidence interval; PICU, pediatric intensive care unit.

Boldface type means P < .05. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45U/L.

[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.181.

Variable	ESKAPEEC n = 174	Non- ESKAPEEC n = 54	Univariate analysis	Logistic Regression Analysis [#]	
			P Value	P Value	Odds Ratio (95% CI)
Hemoglobin (g/L), Median(IQR)	108.0(93.0-144.5)	106.0(90.3-125.0)	0.272		
Platelet count ((*10 ⁹), Median(IQR)	209(111-323)	341(168-439)	< 0.001	0.142	0.999(0.997-1.000)
C-reactive protein (mg/dL), Median(IQR)	15.0(3.0-85.3)	26.5(10.0-116.6)	0.017	0.704	1.001(0.995-1.007)
Elevated ALT, No. (%)	56(32.2)	20(37.0)	0.509		
Elevated AST, No. (%)	90(51.7)	21(38.9)	0.099		
Severity of BSI					
MODS, No. (%)	15(8.6)	6(11.1)	0.777		
Septic shock, No. (%)	13(7.5)	2(3.7)	0.508		
Mechanical ventilation, No. (%)	44(25.3)	13(24.1)	0.857		
PICU admission, No. (%)	31(17.8)	9(16.7)	0.846		
Length of hospital stay (days), Median(IQR)	20.5(10.0-31.0)	14.0(8.8-23.0)	0.023		
7-day mortality	14 (8.0)	4 (7.4)	0.879		
Overall mortality	25 (14.4)	7 (13.0)	0.795		
Inappropriate empirical treatment, No. (%)	46(27.4)	4(7.5)	0.003		
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSI, bloodstream infection; MODS, multiple organ dysfunction syndrome; IQR, interquartile range; CI, confidence interval; PICU, pediatric intensive care unit.					
Boldface type means P < .05. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45U/L.					
[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.181.					

Table 3

Comparison of MRD and non-MRD ESKAPEEC bloodstream infections among hospitalized children.

Variable	MRD- ESKAPEEC	Non-MRD ESKAPEEC	Univariate analysis	Logistic Regression Analysis [#]	
	n = 124	n = 44	P Value	P Value	Odds Ratio (95% CI)
Male, No. (%)	50(40.3)	18(40.9)	0.946		
Age (m),Median(IQR)	2.5(0.5– 26.4)	9.7 (1.0– 72.0)	0.07		
Presence of any underlying disease, No. (%)	90(72.6)	19(43.2)	< 0.001	0.469	1.376(0.581– 3.26)
Premature and/or low birth weight,No. (%)	44(35.5)	10(22.7)	0.120		
Tumor diseases, No. (%)	24(19.4)	5(11.4)	0.228		
Aplastic anemia, No. (%)	3(2.4)	0	0.568		
Congenital heart disease, No. (%)	10(8.1)	1(2.3)	0.327		
Lung disease, No. (%)	11(8.9)	1(2.3)	0.263		
Digestive disease,No. (%)	14(11.3)	1(2.3)	0.135		
Kidney disease,No. (%)	3(2.4)	1(2.3)	1.000		
Other diseases,No. (%)	7(5.6)	3(6.8)	1.000		
Nosocomial infection, No. (%)	51 (41.1)	5 (11.4)	< 0.001	0.037	3.314(1.076– 10.205)
Previous surgery and/ or trauma (within 3 months), No. (%)	20(16.1)	4(9.1)	0.252		
Previous hospitalization (within1 month),No. (%)	27(21.8)	6(13.6)	0.243		
Previous antibiotic use (within 1 month), No. (%)	27(21.8)	19(43.2)	0.006	0.219	0.6(0.266– 1.356)
Likely source of infections					

MDR = multidrug resistant. The interpretation for the other abbreviations were listed in Table 2 legend.

Boldface type means $P < .05$. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45 U/L.

[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.668.

Variable	MRD-ESKAPEEC	Non-MRD ESKAPEEC	Univariate analysis	Logistic Regression Analysis [#]	
	n = 124	n = 44	P Value	P Value	Odds Ratio (95% CI)
Lung infection, No. (%)	27(21.8)	4(9.1)	0.062		
Abdominal infection, No. (%)	20(16.1)	7(15.9)	0.973		
Urinary infection, No. (%)	17(13.7)	9(20.5)	0.288		
Intracranial infection, No. (%)	2(1.6)	0	1.000		
Skin or soft tissue infection, No. (%)	8(6.5)	12(27.3)	< 0.001	0.011	0.245(0.083–0.721)
Primary BSI, No. (%)	55(44.4)	14(31.8)	0.146		
Laboratory findings					
White blood cell count (*10 ⁹), Median(IQR)	9.4(4.9–13.9)	9.8 (7.0–13.3)	0.358		
Neutrophil percentage, Median(IQR)	54.0(33.4–71.0)	58.8 (41.0–76.9)	0.082		
Hemoglobin (g/L), Median(IQR)	110.0 (91.8–150.0)	104.5 (94.0–126.0)	0.424		
Platelet count ((*10 ⁹), Median(IQR)	188 (100–302)	271 (173–413)	0.004	0.076	0.998(0.996–1.000)
C-reactive protein (mg/dL), Median(IQR)	9.5 (3.0–65.8)	32.5 (2.3–150.7)	0.203		
Elevated ALT, No. (%)	39(31.5)	13(29.5)	0.814		
Elevated AST, No. (%)	68(54.8)	18(40.9)	0.112		
Severity of BSI					
MODS, No. (%)	12(9.7)	1(2.3)	0.211		
Septic shock, No. (%)	10(8.1)	0	0.065		
Mechanical ventilation, No. (%)	32(25.8)	10(22.7)	0.685		
PICU admission, No. (%)	18(14.5)	11(25.0)	0.114		
MDR = multidrug resistant. The interpretation for the other abbreviations were listed in Table 2 legend.					
Boldface type means P < .05. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45U/L.					
[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.668.					

Variable	MRD- ESKAPEEC	Non-MRD ESKAPEEC	Univariate analysis	Logistic Regression Analysis [#]	
	n = 124	n = 44	P Value	P Value	Odds Ratio (95% CI)
Length of hospital stay (days),Median(IQR)	24.0 (13.0– 36.0)	14.5 (9.0- 27.3)	0.006		
7-day mortality	8 (6.5)	3 (6.8)	1.000		
Overall mortality	17 (13.7)	5 (11.4)	0.692		
Inappropriate empirical treatment,No. (%)	42(33.9)	4(9.1)	0.002		
MDR = multidrug resistant. The interpretation for the other abbreviations were listed in Table 2 legend.					
Boldface type means P < .05. Elevated ALT means ALT was > 40 U/L. Elevated AST means AST was > 45U/L.					
[#] P value of Hosmer-Lemeshow goodness-of-fit test was 0.668.					

Table 4. Analysis of predictors for mortality in 174 hospitalized children with ESKAPEEC BSI.

Variable	non-survivors n=25	survivors n=149	Univariate analysis	Logistic Regression Analysis [#]	
			P Value	P Value	Odds Ratio (95% CI)
Male, No. (%)	10 (40.0)	61 (40.9)	0.930		
Age (m) Median(IQR)	3.6 (0.8-33.5)	3.0 (0.6-36.0)	0.909		
Presence of any underlying disease, No. (%)	20 (80.0)	91 (61.1)	0.068		
Premature and/or low birth weight No. (%)	8 (32.0)	47 (31.5)	0.964		
Tumor diseases, No. (%)	4 (16.0)	25 (16.8)	1.000		
Aplastic anemia, No. (%)	1 (4.0)	2 (1.3)	0.909		
Congenital heart disease, No. (%)	1 (4.0)	10 (6.7)	0.943		
Lung disease, No. (%)	1 (4.0)	11 (7.4)	0.848		
Digestive disease No. (%)	5 (20.0)	10 (6.7)	0.071		
Kidney disease No. (%)	1 (4.0)	3 (2.0)	1.000		
Other diseases No. (%)	4 (16.0)	7 (4.7)	0.088		
Nosocomial infection, No. (%)	5 (20.0)	51 (34.2)	0.156		
Previous surgery and/ or trauma (within 3 months) No. (%)	8 (32.0)	16 (10.7)	0.011	0.006	7.006 (1.761-27.876)
Previous hospitalization (within 1 month) No. (%)	5 (20.0)	28 (18.8)	1.000		
Previous antibiotic use (within 1 month), No. (%)	2 (8.0)	45 (30.2)	0.021	0.034	0.132 (0.020-0.860)
Likely source of infections					
Lung infection No. (%)	5 (20.0)	26 (17.4)	0.979		
Abdominal infection No. (%)	6 (24.0)	21 (14.1)	0.333		
Urinary infection No. (%)	1 (4.0)	25 (16.8)	0.175		
Intracranial infection No. (%)	0	2 (1.3)	1.000		
Skin or soft tissue infection No. (%)	0	20 (13.4)	0.082		
Primary BSI No. (%)	12 (48.0)	63 (42.3)	0.593		

Laboratory findings						
White blood cell count (*10 ⁹),Median(IQR)	6.9[3.5-11.3]	9.7[5.3-13.9]	0.095			
Neutrophil percentage, Median(IQR)	41.0[9.5-63.1]	58.0[34.8-72.7]	0.019	0.072	0.979	[0.957-1.002]
Hemoglobin (g/L), Median(IQR)	97.0 [72.5-138.0]	110[95-147.5]	0.026	0.218	0.990	[0.973-1.006]
Platelet count ((*10 ⁹), Median(IQR)	134[41-227]	216 [117.5-352.0]	0.002	0.037	0.996	[0.991-1.000]
C-reactive protein (mg/dL), Median(IQR)	29[6-132]	13[3-80.5]	0.068			
Elevated ALT, No. (%)	12[48.0]	44[29.5]	0.067			
Elevated AST, No. (%)	15[60.0]	75[50.3]	0.371			
MODS No. (%)	7[28.0]	8[5.4]	0.001	0.752	1.288	[0.268-6.197]
Septic shock No. (%)	4[16.0]	9[6.0]	0.180			
Blood products transfusion No. (%)	23[92.0]	103[69.1]	0.018	0.581	0.597	[0.096-3.720]
Indwelling catheter No. (%)	19[76.0]	96[64.4]	0.258			
Indwelling gastric tube N[%]	14[56.0]	61[40.9]	0.159			
Central venous catheter N[%]	10[40.0]	66[44.3]	0.689			
Urinary catheter N[%]	2[8.0]	5[3.4]	0.587			
Mechanical ventilation, N[%]	13[52.0]	31[20.8]	0.001	0.004	7.997	[1.906-33.546]
PICU admission, No. (%)	9[36.0]	22[14.8]	0.022	0.137	3.065	[0.701-13.408]
Inappropriate empirical treatment No. (%)	9[40.9]	37[25.3]	0.127			

The interpretation for the abbreviations were listed in Table 2 legend.

Boldface type means $P < .05$. Elevated ALT means ALT was $> 40\text{U/L}$. Elevated AST means AST was $>45\text{U/L}$.

P value of Hosmer-Lemeshow goodness-of-fit test was 0.098.

Figures




Figure 1

Flow diagram for the study patients. BSI, bloodstream infection; MDR, multidrug resistance.